OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Swain on the Impact of Chemotherapy on Outcomes in HER2-Positive Metastatic Breast Cancer

October 15th 2014

Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses a taxane's impact on outcomes in patients with HER2-positive metastatic breast cancer.

Dr. Hudis Discusses Obesity and Breast Cancer

October 15th 2014

Clifford A. Hudis, MD, chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, professor of medicine, Weill Cornell Medical College, discusses obesity and its relation to breast cancer.

Dr. Flinn Discusses the DYNAMO Trial

October 14th 2014

Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses the DYNAMO Trial, which is looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma.

Dr. Antonarakis on AR-V7 and Resistance to AR-Targeting Agents in mCRPC

October 8th 2014

Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses AR-V7 and resistance to AR-targeting agents in men with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Halmos on Detecting Actionable Mutations in Patients With Lung Cancer

October 7th 2014

Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, comments on the detection of actionable mutations in patients with lung cancer.

Dr. Rugo Discusses How Stomatitis Impacts the Efficacy of Everolimus

October 7th 2014

Hope S. Rugo, MD, professor of medicine and director of breast oncology and clinical trials education at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses a meta-analysis that examined how stomatitis impacts the efficacy of everolimus

Dr. Fernandez Discusses Immunotherapy Plus Radiation Therapy for Prostate Cancer

October 6th 2014

Eduardo Fernandez, MD, PhD, FACRO, Senior Vice President, Medical Affairs / Medical Director for Latin America, Radiation Oncologist, 21st Century Oncology, discusses the potential for immunotherapy and radiation therapy to be used together to treat prostate cancer.

Dr. Lamanna Discusses Lymphocytosis Following CLL Treatment

October 3rd 2014

Nicole Lamanna, MD, clinical professor of medicine, Columbia University Medical Center, discusses lymphocytosis following treatment with new, oral CLL agents.

Dr. Rolfo Discusses the Potential Utility of Ceritinib

October 2nd 2014

Christian Rolfo, MD, PhD, MHBA, head, phase I clinical trials unit, Antwerp University Hospital, Belgium, discusses the potential utility of ceritinib.

Dr. Herbst on the Next Generation of Lung Cancer Trials

October 1st 2014

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses next generation lung cancer trials.

Dr. Ledermann Discusses Olaparib in Ovarian Cancer

October 1st 2014

Jonathan Ledermann, BSc, MD, FRCP, Professor of Medical Oncology in the UCL Cancer Institute, University College London, discusses health-related quality of life during olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation.

Dr. Fitch Discusses Dose Escalation of Radiation in Prostate Cancer

September 26th 2014

Dwight L. Fitch, MD, Radiation Oncologist, 21st Century Oncology in Bradenton, Florida, discusses dose modifications for radiation therapy in patients with prostate cancer.

Dr. Blinderman on Early Palliative Care for Patients With Metastatic Disease

September 24th 2014

Craig Blinderman, MD, Attending Physician in Medicine & Anesthesiology NewYork-Presbyterian Hospital/Columbia University Medical Center, Assistant Professor of Palliative Care (Medicine & Anesthesiology), Columbia University, discusses starting palliative care early in patients with metastatic disease.

Gustavo Olivera, PhD, Discusses an Analysis of a Radiation Oncology Registry

September 23rd 2014

Gustavo Olivera, PhD, from 21st Century Oncology, discusses an analysis of a radiation oncology registry.

Dr. Mehta Discusses the Reliability of Automated Segmentation for Lung Volumes in Multiple Cancers

September 23rd 2014

Niraj Mehta, MD, Radiation Oncologist, 21st Century Oncology, discusses the reliability of automated segmentation for lung volumes in breast, lung, and esophageal cancers.

Daniel H. Galmarini Provides an Overview of Adaptive Radiotherapy

September 19th 2014

Daniel H. Galmarini, Chief Technology Officer/Director, Physics and Engineering, 21st Century Oncology, provides an overview of adaptive radiotherapy.

Dr. Lazarus Discusses Companion Diagnostics

September 18th 2014

Tadd Lazarus, MD, Chief Medical Officer, QIAGEN, provides an overview of companion diagnostics.

Dr. Woyach Discusses the Efficacy Findings from the RESONATE Trial

September 18th 2014

Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the efficacy findings from the phase III RESONATE trial.

Dr. Attai Discusses 5-Year Outcomes for APBI With Strut-Based Brachytherapy

September 17th 2014

Deanna J. Attai, MD, discusses a 5-year follow up of patients receiving accelerated partial breast irradiation (APBI) using strut-based applicators.

Dr. Ou on Alectinib as Treatment for NSCLC

September 16th 2014

Sai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses data on alectinib as treatment for patients with non-small cell lung cancer (NSCLC) with brain metastases.